You are here

Article Text

Article menu
Download PDFPDF
Rapid communication
Association of rs2200733 at 4q25 with atrial flutter/fibrillation diseases in an Italian population
  1. C Viviani Anselmi1,
  2. V Novelli1,
  3. R Roncarati1,
  4. A Malovini1,2,
  5. R Bellazzi2,
  6. R Bronzini1,
  7. G Marchese1,
  8. G Condorelli1,
  9. A S Montenero1,
  10. A A Puca1
  1. 1
    Istituto Ricovero Cura Carattere Scientifico “Multimedica”, Milan, Italy
  2. 2
    University of Pavia, Pavia, Italy
  1. Dr A A Puca, Unit of Genetics and Cardiovascular Research Institute, IRCCS Policlinico MultiMedica, Via Milanese 300, 20099 Sesto S Giovanni, Italy; puca{at}longevita.org

Abstract

Background: Atrial fibrillation (AF) and atrial flutter (AFL) are common cardiac conduction disorders affecting many people. Recent studies on sporadic cases of AF/AFL showed a significant association of the single nucleotide polymorphism rs2200733T with the disease, suggesting a genetic factor in the development of the disease.

Objectives: To determine the association of rs2200733 with AF/AFL derived from an Italian population sample.

Subjects: 78 patients with AF/AFL and 348 controls took part in the study.

Design: Genetic case–control study.

Results: The results indicate that there is a positive, significant association between the rs2200733 T allele and patients with AF/AFL of Italian origin (allelic p<0.001 with OR = 2.17).

Conclusion: These results derived from a sample of the Italian population agree with previously reported findings from an Icelandic study, which also found that the minor allele rs2200733 was associated with AF/AFL disease.

https://doi.org/10.1136/hrt.2008.148544

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None for this manuscript. However, for purposes of complete transparency, AAP has a non-funding affiliation with Elixir Pharmaceuticals.

    • Funding: Italian Ministry of Health (1% funds), Italian Ministry of Research and University (FIRB). VN and RR are supported by a fellowship of the Doctorate School of Molecular Medicine, University of Milan, Italy.

    • Ethics approval: Ethics approval was obtained.